Anbio Biotechnology Class A Ordinary Shares Total Assets
Anbio Biotechnology Class A Ordinary Shares total assets. Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) holds total assets worth $30.24 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Anbio Biotechnology Class A Ordinary Sha market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Anbio Biotechnology Class A Ordinary Shares (2021–2025)
Total assets of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See NNNN stock price for real-time trading data and today's change.
Anbio Biotechnology Class A Ordinary Shares - Asset Composition Analysis
Anbio Biotechnology Class A Ordinary Shares Total Assets Breakdown (December 2025)
Anbio Biotechnology Class A Ordinary Shares total assets breakdown as of December 2025. Anbio Biotechnology Class A Ordinary Shares's total assets of $30.24 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.7% |
| Accounts Receivable | $3.66 Million | 12.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Anbio Biotechnology Class A Ordinary Sha current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anbio Biotechnology Class A Ordinary Shares's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 25.7% of total assets in 2025, down from 85.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
Anbio Biotechnology Class A Ordinary Shares Competitors by Total Assets
Key competitors of Anbio Biotechnology Class A Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$1.15 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$2.77 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Anbio Biotechnology Class A Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 344.31 | 35.56 | 9.88 |
| Quick Ratio | 344.31 | 35.56 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.16 Million | $18.24 Million | $12.53 Million |
Anbio Biotechnology Class A Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Anbio Biotechnology Class A Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 33.46 |
| Latest Market Cap to Assets Ratio | 5.20 |
| Asset Growth Rate (YoY) | 59.8% |
| Total Assets | $30.24 Million |
| Market Capitalization | $157.35 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Anbio Biotechnology Class A Ordinary Shares's assets at a significant premium (5.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Anbio Biotechnology Class A Ordinary Shares's assets grew by 59.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual total assets of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $30.24 Million | +59.83% |
| 2024-12-31 | $18.92 Million | +19.67% |
| 2023-12-31 | $15.81 Million | +13.28% |
| 2022-12-31 | $13.96 Million | +183.95% |
| 2021-12-31 | $4.92 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more